These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23991923)

  • 1. Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.
    Lai CM; Horowitz S
    Expert Rev Hematol; 2013 Aug; 6(4):361-73. PubMed ID: 23991923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
    Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
    Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
    Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
    J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
    Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
    de Claro RA; McGinn K; Kwitkowski V; Bullock J; Khandelwal A; Habtemariam B; Ouyang Y; Saber H; Lee K; Koti K; Rothmann M; Shapiro M; Borrego F; Clouse K; Chen XH; Brown J; Akinsanya L; Kane R; Kaminskas E; Farrell A; Pazdur R
    Clin Cancer Res; 2012 Nov; 18(21):5845-9. PubMed ID: 22962441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV; Bartlett NL
    Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
    Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
    Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature.
    Zinzani PL; Sasse S; Radford J; Shonukan O; Bonthapally V
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):359-69. PubMed ID: 25964164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
    Haddley K
    Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.